Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,551 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nervous System Tumors Clear all
Completed No phase listed Observational

Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients

NCT01222728
View directory record Official record
Conditions
Neoplasms, Nervous System Disease, Vestibular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting No phase listed Observational

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

NCT06299748
View directory record Official record
Conditions
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod
Biological
Lead sponsor
argenx
Industry
Eligibility
Female only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Active, not recruiting Not applicable Interventional

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

NCT03820778
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibroma, Atypical Neurofibroma, Atypical Neurofibromatosis, Plexiform Neurofibroma, Von Recklinghausen Disease
Interventions
Whole Body MRI
Diagnostic Test
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

NCT02110706
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jul 21, 2026, 9:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting Phase 4 Interventional

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

NCT06377371
View directory record Official record
Conditions
Meningioma
Interventions
Brain Imaging with [Cu64]DOTATATE, Radio-guided Surgery With Neoprobe Utilization
Diagnostic Test · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

NCT05362409
View directory record Official record
Conditions
High Grade Glioma
Interventions
5 Aminolevulinic Acid, CV01-delivered ultrasound
Drug · Device
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Amherst, New York • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 21, 2026, 9:37 AM EDT
Completed No phase listed Observational

The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study

NCT00824278
View directory record Official record
Conditions
Cancer, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 21 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 9:37 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis

NCT02645487
View directory record Official record
Conditions
Brain Neoplasms, Adult, Malignant
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting Not applicable Interventional

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

NCT05990426
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer
Interventions
FAST Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Active, not recruiting Phase 1 Interventional

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

NCT03465618
View directory record Official record
Conditions
Brain Cancer, Pituitary Adenoma
Interventions
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

NCT00003348
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT02107755
View directory record Official record
Conditions
Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial

NCT01869348
View directory record Official record
Conditions
Obesity, Cardiovascular Disease, Cancer, Diabetes, Sarcopenia
Interventions
Monitor intervention
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

NCT00004189
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, becatecarin, cisplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

NCT02192333
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Depression, Fatigue, Leukemia, Lymphoma, Malignant Bone Neoplasm, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Pain, Sleep Disorder, Soft Tissue Sarcoma
Interventions
Management of Therapy Complications, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

NCT06764940
View directory record Official record
Conditions
HER2-negative Breast Cancer Patients With Brain Metastases
Interventions
Utidelone, Utidelone in combination with capecitabine
Drug
Lead sponsor
Biostar Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Duarte, California • Los Alamitos, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 9:37 AM EDT
Withdrawn Not applicable Interventional

Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography

NCT05516485
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Assessment, Magnetic Resonance Elastography
Other · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Early Phase 1 Interventional

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216
View directory record Official record
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting Not applicable Interventional

ASCENT Intervention for Brain Tumor Patients

NCT06099743
View directory record Official record
Conditions
Malignant Brain Tumor, Glioma, Coping Skills, Distress, Emotional
Interventions
Psychosocial intervention, Usual supportive care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 21, 2026, 9:37 AM EDT
Not listed Phase 3 Interventional Results available

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

NCT00807768
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
533
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 21, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05425004
View directory record Official record
Conditions
Meningioma
Interventions
Cabozantinib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits

NCT05523115
View directory record Official record
Conditions
Anxiety, Stress, Memory Deficits, Cortisol Overproduction
Interventions
Heights Smart Supplement
Dietary Supplement
Lead sponsor
Heights
Industry
Eligibility
21 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 21, 2026, 9:37 AM EDT